Nephron celebrates $215M vaccine expansion 

Nephron Pharmaceuticals CEO Lou Kennedy has reason for optimism. 
Tuesday's beam-raising ceremony marked a milestone for the $215.8 million expansion at Nephron Pharmaceutical Corp.’s Lexington County campus.
The expansion is expected to create 380 jobs and includes a 110,000-square-foot vaccine production, chemotherapy and antibiotic wing.
 Kennedy says she expects it to be up and running by next March. 
Nephron seeks a vaccine production partner for the pre-filled sterile syringes that make up its 503B Outsourcing.
Possibilities include 2 covid vaccine makers, Moderna and Pfizer, which are near release of their drugs. 
Moderna said preliminary data found its vaccine 94.5% effective.
Pfizer announced a 90% effectiveness rate for its vaccine.
Nephron has received FDA approval to run all 12 of its production lines in response to increased demand for its inhalation solutions during the pandemic.
“Our products are not approved for the treatment of covic-19 or its symptoms," Kennedy said.
"We have worked with the FDA to develop and obtain approval of additional prescription product lines, began manufacturing hand sanitizer, and recently opened a CLIA-certified diagnostics lab.” 
The expansion will allow Nephron to make more ingredients it needs as supply chain disruptions have slowed production.

Keep up with the latest news on Nephron Pharmaceuticals on this site.